Drugs / VS 105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03043482 | Jan 2017 → Mar 2018 | end stage renal failure | Vidasym, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS 105 | “multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days” NCT03043482 ↗ |
| Route | Oral | “VS 105 Following Oral Administration” NCT03043482 ↗ |